STOCK TITAN

iBio: Frazier Life Sciences fund reports 3% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

iBio, Inc. (IBIO) beneficial-ownership report shows Frazier Life Sciences Public Fund, L.P. directly holds 1,953,467 common shares, or 3.0% of the class, based on 64,307,256 shares outstanding as of September 30, 2026. FHMLSP, L.P. and FHMLSP, L.L.C. report shared voting and dispositive power over the same shares. The reported position excludes pre-funded warrants to purchase 7,557,258 shares held by the Public Fund, 70,668 held by Frazier Life Sciences XI, L.P., and 886,335 held by Frazier Life Sciences XII, L.P. Exercise of each warrant is subject to a 9.99% beneficial-ownership limitation. Frazier Life Sciences XI, L.P. and Frazier Life Sciences XII, L.P. report no common shares beneficially owned.

Beneficially owned common shares 1,953,467 shares Directly held by Frazier Life Sciences Public Fund, L.P.
Percent of class 3.0% Reported by Frazier Life Sciences Public Fund, L.P.
Common shares outstanding 64,307,256 shares As of September 30, 2026; used as the ownership-percentage basis.
Pre-funded warrants 7,557,258 shares Shares purchasable by warrants held by Frazier Life Sciences Public Fund, L.P.
Pre-funded warrants 70,668 shares Shares purchasable by warrants held by Frazier Life Sciences XI, L.P.
Pre-funded warrants 886,335 shares Shares purchasable by warrants held by Frazier Life Sciences XII, L.P.
Beneficially owned common shares 0 shares each Reported by Frazier Life Sciences XI, L.P. and Frazier Life Sciences XII, L.P.
Beneficial-ownership limitation 9.99% Warrant exercise is restricted if it would exceed this limit immediately after exercise.
Pre-Funded Warrants financial
"holds Pre-Funded Warrants to purchase 7,557,258 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficial ownership limitations regulatory
"exercise of which is subject to certain beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
Shared Voting Power regulatory
"Shared Voting Power 1,953,467.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 1,953,467.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much IBIO stock did Frazier Life Sciences Public Fund report?

Frazier Life Sciences Public Fund, L.P. reported beneficial ownership of 1,953,467 iBio common shares, or 3.0% of the class. The percentage is based on 64,307,256 shares outstanding as of September 30, 2026.

How many IBIO shares can Frazier Life Sciences funds acquire through pre-funded warrants?

Frazier Life Sciences Public Fund, L.P. holds pre-funded warrants to purchase 7,557,258 shares; Frazier Life Sciences XI, L.P. holds warrants for 70,668 shares; and Frazier Life Sciences XII, L.P. holds warrants for 886,335 shares. Exercise is restricted if it would cause the holder, its affiliates, or persons acting as a group to exceed 9.99% ownership immediately after exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





451033708

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 64,307,256 shares of Common Stock outstanding on September 30, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 64,307,256 shares of Common Stock outstanding on September 30, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A. The percentage listed in row 11 is calculated based on 64,307,256 shares of Common Stock outstanding on September 30, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 do not include any warrants held by the Reporting Person. See item 4(a) to this Schedule 13G/A.


SCHEDULE 13G



Frazier Life Sciences Public Fund, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:11/16/2026
FHMLSP, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:11/16/2026
FHMLSP, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:11/16/2026
Frazier Life Sciences XI, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:11/16/2026
FHMLS XI, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:11/16/2026
FHMLS XI, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:11/16/2026
Frazier Life Sciences XII, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:11/16/2026
FHMLS XII, L.P.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:11/16/2026
FHMLS XII, L.L.C.
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on May 12, 2026)

Keep reading